Summary

Childhood obesity has increased over the last decade. Due to altered pharmacokinetics (PK) associated with obesity, dosing for anti-epileptics in obese children may vary from that in non-obese children.  Inappropriate dosing may increase the risk for drug toxicity or therapeutic failure.  PK studies are urgently needed to determine appropriate dosing strategies for anti-epileptics in obese children.

The Pharmacokinetics of Anti-epileptic Drugs in Obese Children (AED) study will enroll approximately 100 children, 2 to < 18 years of age, with a body mass index (BMI) > 95th percentile, who are receiving levetiracetum, valproic acid, topiramate, or oxcarbazepine, per standard of care.

Publications